Deadline: 05-Aug-2025
Pfizer is now accepting applications for its Research Competitive Grant to support prospective, active surveillance studies of pneumococcal carriage in healthy children. The goal is to better understand the distribution of pneumococcal serotypes in pediatric populations.
Applicants are encouraged to address current evidence gaps by conducting observational studies. These studies should focus on pneumococcal prevalence and serotype distribution in healthy children. This may include children in daycare, vaccination centers, nursery schools, or those with respiratory infections in various healthcare settings.
The studies can take place before or after the implementation of pneumococcal conjugate vaccine (PCV) programs. Topics may cover carriage prevalence, acquisition, duration, or density using up-to-date methodologies. Applicants can also explore innovative methods to more accurately assess the carriage burden or track serotype distribution in general or high-risk populations.
The research can include documenting the population-level impact of PCV introduction on pneumococcal carriage. Up to six projects will be selected, with a total available fund of USD 200,000. Each selected project should be completed within 12–18 months of receiving funding.
This opportunity is open to institutions based in Southeast Asia, including India, Indonesia, Malaysia, Philippines, Singapore, Taiwan, Thailand, and Vietnam. Only organizations are eligible to apply—individuals and unaffiliated medical practice groups are not eligible.
Projects involving multiple departments or institutions are acceptable if all parties have defined roles and the applying organization plays a central role. The principal investigator must hold a medical or doctoral degree (MD, PhD, or equivalent), or an advanced nursing, pharmacy, physiotherapy, or social work degree.
The PI must be affiliated with the applying organization as an employee or contractor, and the organization must be legally able to receive funds from Pfizer International LLC. Indian applicants must possess a valid FCRA certificate to be eligible.
For more information, visit Pfizer.
